☆ 4.7 Article

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

B7-H3: An Attractive Target for Antibody-based Immunotherapy

Filippos Kontos et al.

Summary: B7-H3, as a potential target for antibody-based immunotherapy, is overexpressed in malignant tissues and associated with poor prognosis. Although the receptor for B7-H3 remains unknown, various antibody-based strategies targeting B7-H3-expressing cancer cells have been developed, demonstrating potent antitumor activity in preclinical models. Ongoing clinical trials are evaluating the safety and efficacy of these strategies in patients, with the hope of enhancing the therapeutic efficacy of tumor immunity.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

添加到收藏夹

Review Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow et al.

Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

G. Obara et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Kohei Shitara et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer

Hossein Borghaei et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

添加到收藏夹

Article Oncology

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Young Kwang Chae et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Immunology

Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials

Bo Zhang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2018)

添加到收藏夹

Article Oncology

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Abstracts

[Anonymous]

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

Mehmet Altan et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Cell Biology

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Young-hee Lee et al.

CELL RESEARCH (2017)

添加到收藏夹

Article Oncology

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

Elodie Picarda et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Immunology

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

John Powderly et al.

Journal for ImmunoTherapy of Cancer (2015)

添加到收藏夹

Article Oncology

Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Deryk Loo et al.

CLINICAL CANCER RESEARCH (2012)

添加到收藏夹

Article Oncology

Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis

Akihiro Katayama et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Review Oncology

Dose Escalation Methods in Phase I Cancer Clinical Trials

Christophe Le Tourneau et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

添加到收藏夹

Article Oncology

B7-H3 and B7-H4 expression in non-small-cell lung cancer

Yuping Sun et al.

LUNG CANCER (2006)

添加到收藏夹

Article Immunology

Murine B7-H3 is a negative regulator of T cells

DVR Prasad et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

Article Immunology

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

WK Suh et al.

NATURE IMMUNOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.